Solubility based Biowaiver [Dissolution / BCS / IVIVC]

posted by Obinoscopy  – USA, 2018-10-01 17:05 (792 d 06:47 ago) – Posting: # 19357
Views: 4,267

Dear Amalia

» Basically it is an additional strength biowaiver.

Okay

» The molecule is classified as BCS Class II.

Okay. I'll like to point out that BCS classification is irrelevant when following the Additional Strength Biowaiver pathway. What's relevant is to confirm if Invivo Bioequivalence was established for the Highest Strength of your formulation. And that both strengths are in the same proportion in terms of excipients.

» However we were advised that considering solely the lowest strength, it is very close to being considered as highly soluble.

Who gave the advice? A Regulatory Agency? A CRO?

» As per the Guideline of BE "the drug substance i considered highly soluble if the highest single dose administered as immediate release formulation is completely dissolved in 250ml of buffers within certain pH range". In other words for a highly soluble drug, the dose number (D0) is equal or lower than 1.

Again I'll reiterate that solubility of the drug substance is irrelevant. See above.

» Therefore, my question here is whether the solubility test should be done at the API or the final formulation (lowest strength) in order to support a biowaiver for the lowest stength.

Following the Additional Strength Biowaivers pathway, you don't need to perform solubility test for the API. what you do is to perform a comparative dissolution profile study for your low strength formulation against the high strength formulation after you've ensured that the requirements I stated above have been met.

» I hope I have not confused you more!

Lol, I think not. I hope i haven't confused you as well.

Regards,

Scopy

Complete thread:

Activity
 Admin contact
21,225 posts in 4,427 threads, 1,482 registered users;
online 7 (1 registered, 6 guests [including 2 identified bots]).
Forum time: Tuesday 23:52 UTC (Europe/Vienna)

A big data-analyst is an expert
in producing misleading conclusions from huge datasets.
It is much more efficient to use a statistician,
who can do the same with small ones.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5